低级别胶质瘤（LGG）的液体活检研究相对于其他恶性脑肿瘤来说显得不太明显。可靠的血清标记物对于诊断、随访和治疗很宝贵。我们提出了一个临床实用性评分（CUS），用于评估LGG中生物标志物的临床实用性。我们进行了一项PRISMA综述。我们对每个生物标志物进行了检查，并根据CUS和证据级别（LOE）对其进行了分类。我们确定了四类生物标志物：（1）循环蛋白-（a）vitronectin能区分LGG和HGG（敏感性：98％，特异性：91％，CUS：3，LOE：III），（b）CTLA-4能区分LGG和HGG，（截断值：220.43 pg/ml，敏感性：82％，特异性：78％，CUS：3，LOE：III），（c）术前TGF b1能预测星形细胞瘤（截断值：2.52 ng/ml，敏感性：94.9％，特异性：100％，CUS：3，LOE：VI）。 （2）微小RNA（miR）-（a）miR-16能区分WHO IV和WHO II和III组（AUC = 0.98，CUS：3，LOE：III），（b）miR-454-3p在HGG中的水平高于LGG（p = 0.013，CUS：3，LOE：III），（c）miR-210的表达与WHO分级有关（敏感性83.2％，特异性94.3％，CUS：3，LOE：III）。 （3）循环DNA-（a）IDH1R132H突变通过组合使用COLD和数字PCR在血浆中检测到（敏感性：60％，特异性：100％，CUS：3，LOE：III）。 4.外泌体-（a）SDC1血清水平可以区分GBM和LGG（敏感性：71％，特异性：91％，CUS：2C，LOE：VI）。 我们的研究表明，miR似乎具有最高的临床实用性。评估的研究的LOE通常较低。可以考虑使用不同生物标志物和传统诊断方法的综合方法。我们确定了LGG产生的四类主要生物标志物。我们检查了每个生物标志物，并根据临床实用性评分（CUS）和证据级别（LOE）对其进行了分类。微小RNA（miR）似乎具有最高的CUS和LOE。© 2023. 作者。

Liquid biopsy research on Low-Grade gliomas (LGG) has remained less conspicuous than that on other malignant brain tumors. Reliable serum markers would be precious for diagnosis, follow- up and treatment. We propose a clinical utility score (CUS) for biomarkers in LGG that mirrors their clinical usefulness. We conducted a PRISMA review. We examined each biomarker classifying them by CUS and Level of Evidence (LOE). We identified four classes of biomarkers: (1). Circulating protein-(a) vitronectin discriminates LGG from HGG (Sn:98%, Sp:91%, CUS: 3, LOE: III), (b) CTLA-4 discriminates LGG from HGG, (cutoff: 220.43 pg/ml, Sn: 82%, Sp: 78%, CUS:3, LOE:III), (c) pre-operative TGF b1 predict astrocytoma (cutoff: 2.52 ng/ml, Sn: 94.9%, Sp: 100%, CUS:3, LOE:VI). (2). micro-RNA (miR)-(a) miR-16 discriminates between WHO IV and WHO II and III groups (AUC = 0.98, CUS:3, LOE: III), (b) miR-454-3p is higher in HGG than in LGG (p = 0.013, CUS:3, LOE: III), (c) miR-210 expression is related to WHO grades (Sn 83.2%, Sp 94.3%, CUS: 3, LOE: III). (3). Circulating DNA-(a) IDH1R132H mutation detected in plasma by combined COLD and digital PCR (Sn: 60%, Sp: 100%, CUS: 3, LOE: III). 4. Exosomes-(a) SDC1 serum levels could discriminate GBM from LGG (Sn: 71%, Sp: 91%, CUS: 2C, LOE: VI). Our investigation showed that miRs appear to have the highest clinical utility. The LOE of the studies assessed is generally low. A combined approach between different biomarkers and traditional diagnostics may be considered. We identified four main classes of biomarkers produced by LGG. We examined each biomarker, classifying them by clinical utility score (CUS) and level of evidence (LOE). Micro-RNA (miRs) appears to have the highest CUS and LOE.© 2023. The Author(s).